Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. September 2018 08:00 ET | Quelle: NeuroRx, Inc.

NeuroRx to Present at the Annual Rodman & Renshaw Global Investment Conference on Sept 5, 2018

WILMINGTON, Del., Sept. 05, 2018 (GLOBE NEWSWIRE) -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation...
04. September 2018 09:10 ET | Quelle: NeuroRx, Inc.

NeuroRx Announces Phase 2 Data from NRX-101, Initiates Pivotal Study for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)

WILMINGTON, De. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation...
07. Mai 2018 07:00 ET | Quelle: NeuroRx, Inc.

NeuroRx Receives Special Protocol Agreement (SPA) and Biomarker Letter of Support from FDA for Pivotal Studies of NRX-101 to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation & Behavior

WILMINGTON, Del., May 07, 2018 (GLOBE NEWSWIRE) -- NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute...